Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Capital Leases (2016 - 2019)

Historic Capital Leases for Enanta Pharmaceuticals (ENTA) over the last 5 years, with Q3 2019 value amounting to $200000.0.

  • Enanta Pharmaceuticals' Capital Leases fell 3174.06% to $200000.0 in Q3 2019 from the same period last year, while for Sep 2019 it was $200000.0, marking a year-over-year decrease of 3174.06%. This contributed to the annual value of $200000.0 for FY2019, which is 3174.06% down from last year.
  • As of Q3 2019, Enanta Pharmaceuticals' Capital Leases stood at $200000.0, which was down 3174.06% from $224000.0 recorded in Q2 2019.
  • In the past 5 years, Enanta Pharmaceuticals' Capital Leases ranged from a high of $529000.0 in Q3 2015 and a low of $175000.0 during Q2 2015
  • Over the past 5 years, Enanta Pharmaceuticals' median Capital Leases value was $368500.0 (recorded in 2017), while the average stood at $364166.7.
  • Its Capital Leases has fluctuated over the past 5 years, first skyrocketed by 17314.29% in 2016, then plummeted by 3174.06% in 2019.
  • Quarter analysis of 5 years shows Enanta Pharmaceuticals' Capital Leases stood at $513000.0 in 2015, then decreased by 14.23% to $440000.0 in 2016, then fell by 18.64% to $358000.0 in 2017, then fell by 24.3% to $271000.0 in 2018, then dropped by 26.2% to $200000.0 in 2019.
  • Its Capital Leases was $200000.0 in Q3 2019, compared to $224000.0 in Q2 2019 and $249000.0 in Q1 2019.